# Enricnk

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enricnk

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.ruitherapeutics.com
- Total disclosed funding: $29M
- Latest round: Series A (Sep 15, 2025)
- Investors on record: 8

## About

Founded in 2021 and based in Nanjing, China, Nanjing Enrui Kainuo Biotechnology Co., Ltd. develops CAR-NK and CAR-T cell therapies to treat autoimmune, inflammatory, fibrotic, and genetic diseases through precision immunomodulation and advanced biologic platforms.

## Funding rounds

- Series A, Sep 15, 2025, $28M — Green Pine Capital Partners, Shenzhen Capital Real Estate Fund, Nanshan Venture Capital, Hengqin Financial Investment, Tasly Capital Holdings Limited, Shenzhen Nanshan Huirong Investment, Fenshare Holding
- Angel, Jun 30, 2022, $0.8M — Tsinghua Innovation Ventures

## Investors

- Tsinghua Innovation Ventures (https://capitalatlas.ai/funds/tsinghua-innovation-ventures) — Angel
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Nanshan Venture Capital (https://capitalatlas.ai/funds/nanshan-venture-capital) — Series A
- Hengqin Financial Investment (https://capitalatlas.ai/funds/hengqin-financial-investment) — Series A
- Tasly Capital Holdings Limited (https://capitalatlas.ai/funds/tasly-capital-holdings-limited) — Series A
- Shenzhen Nanshan Huirong Investment — Series A
- Fenshare Holding — Series A